Immunos Therapeutics
Business Services · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Wagistrasse 14, Schlieren, Zurich, 8952,...Website
www.immunostherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Immunos Therapeutics
ImmunOs Therapeutics AG, founded in 2014 and headquartered in Zurich, Switzerland, is a clinical-stage biotechnology company focused on discovering and developing next-generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity. Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunos Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Immunos Therapeutics recently announced quarterly report
Immunos Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Immunos Therapeutics has new funding data
Click to see if Immunos Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Immunos Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Immunos Therapeutics is spiking on competitors!
Product Launch: Get notified when Immunos Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Immunos Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Immunos Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immunos Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immunos Therapeutics.
Immunos Therapeutics financials insights
Gather financial insights about Immunos Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$15.2M
2022
Series B
$73M
2024
Series C
$11M
Immunos Therapeutics Tech Stack
A closer look at the technologies used by Immunos Therapeutics
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Promotion
Executive Move
Executive Moves, Promotion
Funding
Funding
Event
Events
Funding
Immunos Therapeutics News & Media
ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors
Schlieren, Switzerland, October 20, 2025 – ImmunOs Therapeutics AG, a clinical-stage biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases, today announced encouraging preliminary results from its ongoing Phase I clinical trial evaluating IOS-1002 in patients with advanced solid tumors.In other news this week: Flink raises €134.6M, SweGaN scores €12M, Samara bags €10.5M ...
Here’s a brief roundup of news we have missed this week (September 16 - 20).ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
September 17, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a Series C financing round of $11 million. The round was led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures as well as other existing investImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its HLA-based technology platform to develop first-in-class and innovative therapeutics for the treatment of cancer and autoimmune diseases, today announced the expansion of its ongoing Phase I clinical trial of IOS-1002 in combination with MSD (Merck & Co., Inc., Rahway, NJ, USA)'s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of advanced solid tumors.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Immunos Therapeutics
Sign Up For FreeTo access detailed company insights
ImmunOs Therapeutics AG, founded in 2014 and headquartered in Zurich, Switzerland, is a clinical-stage biotechnology company focused on discovering and developing next-generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity. Their mission is to develop the next generation of novel therapeutics that will... Read More
